Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients Christine L Lau, MD, Scott M Palmer, MD, Katherine E Posther, BA, David N Howell, MD, PhD, Nancy L Reinsmoen, PhD, H.Todd Massey, MD, Victor F Tapson, MD, James J Jaggers, MD, Thomas A D’Amico, MD, R.Duane Davis, MD The Annals of Thoracic Surgery Volume 69, Issue 5, Pages 1520-1524 (May 2000) DOI: 10.1016/S0003-4975(00)01224-8
Fig 1 Kaplan-Meier comparison of survival between high and low PRA. The Annals of Thoracic Surgery 2000 69, 1520-1524DOI: (10.1016/S0003-4975(00)01224-8)
Fig 2 Immunohistochemical staining for complement (C3) showing deposition in a pattern outlining capillary walls from a patient with a high PRA. This staining is evidence of humoral-mediated lung injury. The Annals of Thoracic Surgery 2000 69, 1520-1524DOI: (10.1016/S0003-4975(00)01224-8)
Fig 3 Histopathologic examination of biopsy from same patient as Figure 2 showing marked alveolar capillaritis accompanied by endothelial swelling and margination of inflammatory cells (hematoxylin and eosin, ×520). The Annals of Thoracic Surgery 2000 69, 1520-1524DOI: (10.1016/S0003-4975(00)01224-8)
Fig 4 Proposed treatment scheme for lung transplant recipients with elevated pretransplant PRA. The Annals of Thoracic Surgery 2000 69, 1520-1524DOI: (10.1016/S0003-4975(00)01224-8)